

Abstract of the Disclosure

There are disclosed compounds of formulae (I) or (II) in which A is selected from the group consisting of (1), (2), (3) and (4); OH, and one of R₁ and R₂ is selected from H, OH and OCH₃, and the other of R₁ and R₂ is selected from OH and OCH₃; one of R₃ and R₄ is selected from H, OH and OCH₃, and the other of R₃ and R₄ is selected from OH and OCH₃; provided that at least one of the pairs R₁, R₂ and R₃, R₄ are both OH; R₅ is selected from OH and OCH₃; and ----- denotes a single or double bond; and pharmaceutically acceptable salts and prodrugs thereof. The compounds of the invention are useful for the treatment of hormone-dependent conditions and cancers.

Cross-References to Related Applications

This application is a U.S. national counterpart application of international application serial No. PCT/AU00/00392 filed May 1, 2000, which claims priority to Australian provisional application serial no. PQ0082 filed April 30, 1999.

2012101808012402

A

16. (Amended) The method according to claim 13 wherein said hormone dependent condition is selected from the group consisting of hormone dependent cancers, hormone dependent cardiovascular disorders and hormone dependent menopausal disorders.

10013308

2012042402

4

23. The method according to claim 14 wherein said hormone dependent condition is selected from the group consisting of hormone dependent cancers, hormone dependent cardiovascular disorders and hormone dependent menopausal disorders.

2018-01-01 10:00:00

INDS02 MJE 411337v1




A



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C07D 311/38, C07C 49/245, 49/248, 49/747, C12N 1/00, A23L 1/30, A61K 31/353, A61P 35/00</p>	A1	<p>(11) International Publication Number: WO 00/66576</p> <p>(43) International Publication Date: 9 November 2000 (09.11.00)</p>
<p>(21) International Application Number: PCT/AU00/00392</p> <p>(22) International Filing Date: 1 May 2000 (01.05.00)</p> <p>(30) Priority Data: PQ0082 30 April 1999 (30.04.99) AU</p> <p>(71) Applicant (for all designated States except US): G.J. CONSULTANTS PTY LTD [AU/AU]; 21 Kooloona Crescent, West Pymble, NSW 2073 (AU).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): JOANNOU, George, Eustace [AU/AU]; 21 Kooloona Crescent, West Pymble, NSW 2073 (AU).</p> <p>(74) Agent: SPRUSON & FERGUSON; GPO Box 3898, Sydney, NSW 2001 (AU).</p>		<p>(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. With amended claims.</p>

(54) Title: ISOFLAVONE METABOLITES



(57) Abstract

There are disclosed compounds of formulae (I) or (II) in which A is selected from the group consisting of (1), (2), (3) and (4); OH, and one of R₁ and R₂ is selected from H, OH and OCH₃, and the other of R₁ and R₂ is selected from OH and OCH₃; one of R₃ and R₄ is selected from H, OH and OCH₃, and the other of R₃ and R₄ is selected from OH and OCH₃; provided that at least one of the pairs R₁, R₂ and R₃, R₄ are both OH; R₅ is selected from OH and OCH₃; and ----- denotes a single or double bond; and pharmaceutically acceptable salts and prodrugs thereof. The compounds of the invention are useful for the treatment of hormone-dependent conditions and cancers.